한빛사논문
- 조회633
Eunjung Kima,b, Eun-Kyung Limc,d, Geunseon Parke, Chaewon Parke, Jong-Woo Lime, Hyo Leee, Woonsung Naf, Minjoo Yeomg, Jinyoung Kime, Daesub Songg,* and Seungjoo Haame,*
aDepartment of Bioengineering and Nano-Bioengineering, Incheon National University, Incheon 22012, Republic of Korea
bDivision of Bioengineering, Incheon National University, Incheon 22012, Republic of Korea
cBioNanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea
dDepartment of Nanobiotechnology, KRIBB School of Biotechnology, UST, Daejeon 34113, Republic of Korea
eDepartment of Chemical and Biomolecular Engineering, Yonsei University, 50 Yonsei-ro, Seoul 03722, Republic of Korea
fCollege of Veterinary Medicine,Chonnam National University, Gwangju 61186, Republic of Korea
gCollege of Pharmacy, Korea University, Sejong-ro, Sejong 30019, Republic of Korea
E.K., E.-K.L., G.P., and C.P. contributed equally to this work.
*To whom correspondence should be addressed.
Abstract
While the coronavirus disease (COVID‐19) accounts for the current global pandemic, the emergence of other unknown pathogens, named “Disease X,” remains a serious concern in the future. Emerging or re‐emerging pathogens continue to pose significant challenges to global public health. In response, the scientific community has been urged to create advanced platform technologies to meet the ever‐increasing needs presented by these devastating diseases with pandemic potential. This review aims to bring new insights to allow for the application of advanced nanomaterials in future diagnostics, vaccines, and antiviral therapies, thereby addressing the challenges associated with the current preparedness strategies in clinical settings against viruses. The application of nanomaterials has advanced medicine and provided cutting‐edge solutions for unmet needs. Herein, an overview of the currently available nanotechnologies is presented, highlighting the significant features that enable them to control infectious diseases, and identifying the challenges that remain to be addressed for the commercial production of nano‐based products is presented. Finally, to conclude, the development of a nanomaterial‐based system using a “One Health” approach is suggested. This strategy would require a transdisciplinary collaboration and communication between all stakeholders throughout the entire process spanning across research and development, as well as the preclinical, clinical, and manufacturing phases.
Keywords : antiviral therapeutics, diagnostic tools, emerging viral diseases, nanomaterials, nanovaccines
논문정보
- Review Paper
- 2021년 02월 (BRIC 등록일 2021-03-11)
- 국내 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 ID
관련분야 연구자보기
관련분야 논문보기
